Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

WILLIS TOWERS WATSON PLC Director's Dealing 2021

May 20, 2021

30135_mrq_2021-05-20_463fd1d7-0b46-4841-a7c5-851c87252a2a.html

Director's Dealing

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

RNS Number : 3419Z

Willis Towers Watson PLC

20 May 2021

Ap9

APPENDIX 3 DISCLOSURE FORMS

FORM 8.1(a)&(b)(i)

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1.       KEY INFORMATION

Name of person dealing (Note 1) Victor F Ganzi
Company dealt in Willis Towers Watson plc
Class of relevant security to which the dealings being disclosed relate (Note 2) Ordinary Shares of $0.000304635 each
Date of dealing 11 May 2021

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long Short
Number (%) Number (%)
(1) Relevant securities 20,386 ordinary shares
(2) Derivatives (other than options) N/A
(3) Options and agreements to purchase/sell 1,646 RSUs - total amount granted on 11 May 2021 and vesting on earlier of May 11, 2022 and the Issuer's 2022 Annual General Meeting of Shareholders
Total 22,032 (0.017%)

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities N/A
(2) Derivatives (other than options) N/A
(3) Options and agreements to purchase/sell N/A
Total N/A

Ap10

3.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale Number of relevant securities Price per unit (Note 5)

(b)      Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit

(Note 5)

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name,

e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)
RSUs Grant 1,646 N/A N/A N/A N/A
RSUs Withheld for tax 1,049 N/A N/A N/A US$264.25
RSUs Vesting 1,135 N/A N/A N/A N/A

(ii)      Exercising

Product name,

e.g. call option
Number of securities Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)
Details Price per unit

(if applicable) (Note 5)

Ap11

4.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and 

any other person relating to the voting rights of any relevant securities under any option referred to 

on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to 

which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            YES/NO

Date of disclosure 11 May 2021
Contact name Cindy Hanna
Telephone number +1 (212) 915-7994
Name of offeree/offeror with which acting in concert Willis Towers Watson plc
Specify category and nature of acting in concert status Director

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEPPUCUAUPGGAU